Is there a better test than a mammogram?

It is a fair question. Mammograms can be uncomfortable, they miss some cancers, and newer technology is easy to find in the news. This page looks at what mammography does well and less well, what 3D mammography adds, when ultrasound or MRI are used alongside it, and where blood tests fit. It replaces an older question about whether breast cancer shows up in blood work.

Screening policy differs between countries and between people. Your own doctor or screening service has the final word on what applies to you, and guidance can change over time.

What mammography does well

Screening aims to find cancer before it causes symptoms. The National Cancer Institute (NCI) says breast cancer screening has been found to reduce deaths from breast cancer, with mammography the standard test for most women.11National Cancer Institute: Screening for Breast Cancer Page dated August 2025; screening reduces deaths; mammography is the standard test. The US Preventive Services Task Force, in a recommendation published in April 2024, advised a mammogram every 2 years for women aged 40 to 74.22US Preventive Services Task Force: Breast Cancer Screening Final recommendation statement of April 30, 2024; biennial mammography for ages 40 to 74. The American Cancer Society adds that most breast cancers can be seen on a mammogram even in people with dense breast tissue.33American Cancer Society: Breast Density and Your Mammogram Report Last revised September 2024; most cancers are visible even in dense breasts.

Where mammography falls short

No screening test is perfect. The American Cancer Society reports that screening mammograms miss about 1 in 8 breast cancers, and that false-positive results, where a mammogram looks abnormal but there is no cancer, are more common in people who are younger, have dense breasts, have had breast biopsies, have breast cancer in the family or take estrogen.44American Cancer Society: Limitations of Mammograms Last revised July 2026; missed cancers and groups with more false positives. The NCI also names overdiagnosis, meaning cancers found that might never have caused problems, and a very small radiation risk.11National Cancer Institute: Screening for Breast Cancer Page dated August 2025; lists false positives, overdiagnosis, delayed diagnosis and radiation. The page on benefits and harms goes further.

Dense breast tissue is a particular problem. It looks white on a mammogram, as can a tumor, so cancers can be harder to see. The NCI says mammography is less sensitive in dense breasts, meaning it is more likely to miss cancer.55National Cancer Institute: Dense Breasts: Answers to Commonly Asked Questions Mammography is less sensitive in dense breasts; dense tissue appears white. See dense breasts and screening.

What 3D mammography adds

Three-dimensional mammography (digital breast tomosynthesis) assembles many images into thin slices. The American Cancer Society says it appears to lower the chance of being called back and to find some cancers better, with a possible benefit in dense breasts, though it often costs more.66American Cancer Society: Mammograms Last revised July 2026; lower callbacks, better detection of some cancers, higher cost. An NCI summary for clinicians describes a systematic review of studies with 488,099 patients in which 3D alone, or 3D combined with standard digital mammography, was more sensitive than standard digital mammography alone.77National Cancer Institute: Breast Cancer Screening (PDQ) Summary for clinicians dated February 2026; tomosynthesis sensitivity review. The Task Force, for its part, calls both approaches effective and does not rank one above the other.22US Preventive Services Task Force: Breast Cancer Screening Final recommendation statement of April 30, 2024; both digital mammography and tomosynthesis are effective.

When ultrasound or MRI are added

For people at higher risk, the American Cancer Society recommends a yearly MRI along with a yearly mammogram, for example with a known BRCA1 or BRCA2 gene change or a lifetime risk of about 20% to 25% or greater.88American Cancer Society: Breast Cancer Screening Guidelines Last revised July 2026; MRI plus mammogram for higher-risk groups. In the UK, Cancer Research UK reports that guidelines recommend yearly MRI scans from age 30 for a BRCA1 or BRCA2 gene change and from age 20 for a TP53 change.99Cancer Research UK: Breast screening (mammography) Last reviewed May 2026; yearly MRI for certain gene changes. Read what makes you high risk for the factors involved.

For dense breasts the evidence is less settled. The American Cancer Society says that experts do not agree what other tests, if any, should be added, and that ultrasound and MRI can find some cancers a mammogram cannot but also show more findings that are not cancer, leading to more tests and biopsies.33American Cancer Society: Breast Density and Your Mammogram Report Last revised September 2024; experts disagree about extra tests. The Task Force concluded that evidence is insufficient to assess the balance of benefits and harms of supplemental ultrasound or MRI in women with dense breasts and a negative mammogram.22US Preventive Services Task Force: Breast Cancer Screening Final recommendation statement of April 30, 2024; an I statement on supplemental screening. A trial described by the NCI found that adding ultrasound to 3D mammography modestly improved cancer detection in women with dense breasts and also increased false-positive recalls.77National Cancer Institute: Breast Cancer Screening (PDQ) Summary for clinicians dated February 2026; describes the DBTUST trial.

Why blood tests are not screening tests

Many people ask whether breast cancer shows up in routine blood work. It does not, in the sense of a test used to screen healthy people. The American Cancer Society describes blood tests in breast cancer as used to help diagnose, choose treatment or monitor a cancer, including tests for circulating tumor DNA that can track treatment.1010American Cancer Society: Breast Cancer Gene, Protein, and Blood Tests Describes blood tests for diagnosis, treatment choice and monitoring. Cancer Research UK says tumor marker tests are not reliable enough to use on their own to diagnose breast cancer, because non-cancerous conditions can also raise the levels.1111Cancer Research UK: Tests for breast cancer Last reviewed April 2026; tumor markers are not reliable alone.

A 2020 peer-reviewed review of non-invasive biomarkers found that existing blood markers are mainly used to monitor therapy in advanced disease and that none has been used alone for screening, because of low sensitivity for early disease or lack of specificity. It also noted that most newer markers remain at early stages of validation.1212Cancers (journal, via PubMed Central): Non-Invasive Biomarkers for Early Detection of Breast Cancer Published September 2020; no blood marker used alone for screening. The screening tests the NCI lists are all imaging or physical exams.11National Cancer Institute: Screening for Breast Cancer Page dated August 2025; lists mammography, MRI, ultrasound, clinical exam and self-exam. Research continues, so this may change.

No single test fits everyone

The better question may be which combination suits a particular person. Age, breast density, family history, gene changes, cost and local availability all play a part. The main guide and the pages on screening methods and thermography help with the wider picture.